Online inquiry

IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ380MR)

This product GTTS-WQ380MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TYRP1 gene. The antibody can be applied in Malignant melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000550.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7306
UniProt ID P17643
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ380MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7931MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ9789MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ3383MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ1850MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ13755MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ3618MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ8569MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ6640MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW